Literature DB >> 14614913

Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input.

P J Goadsby1, J D Classey.   

Abstract

Development of serotonin (5HT(1B/1D)) agonists for the acute attack of migraine resulted in considerable interest in their action. The superior sagittal sinus (SSS) was isolated in alpha-chloralose (60 mg/kg, i.p. and 20 mg/kg i.v.i. supplementary 2 hourly) anaesthetised cats. The SSS was stimulated electrically (100 V, 250 micros duration, 0.3 Hz) and neurons of the trigeminocervical complex monitored using electrophysiological methods. To test 5-HT(1B) receptor-mediated activity common carotid blood flow (CCF) was monitored with a transonic flow probe placed around the vessel. Naratriptan (5-HT(1B/1D/1F) receptor agonist) and alniditan (5-HT(1B/1D) receptor agonist) produced reductions in carotid blood flow of 38+/-5% and 42+/-6%, respectively. These effects were attenuated by the 5-HT(1B) receptor antagonist SB224289 (P<0.05). LY344864 (5-HT(1F) receptor agonist) had no effect on CCF. Naratriptan inhibited SSS-evoked activity (61+/-7%), an effect partially inhibited by the 5-HT(1B) receptor antagonist SB224289 (30+/-5%), or by the 5-HT(1D) receptor antagonist BRL-15572 (37+/-6%). There remained an inhibitory effect of naratriptan after both 5-HT(1B) and 5-HT(1D) receptor blockade (22+/-5%). Alniditan inhibited SSS-evoked trigeminal activity (53+/-6%), an effect abolished after 5-HT(1B) and 5-HT(1D) receptor blockade. LY344864 (5-HT(1F) receptor agonist) inhibited SSS-evoked trigeminal activity (28+/-5%), an effect unaltered by either SB224289 or BRL-15572. It can be concluded that there are inhibitory 5-HT(1B), 5-HT(1D) and 5-HT(1F) receptors in the trigeminocervical complex of the cat. 5-HT(1B) receptor-mediated inhibition is the most potent of the three in terms of inhibition of trigeminovascular nociceptive traffic.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14614913     DOI: 10.1016/s0306-4522(03)00570-0

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  20 in total

1.  Headache.

Authors:  Peter J Goadsby
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

2.  Neurologic bases for comorbidity of balance disorders, anxiety disorders and migraine: neurotherapeutic implications.

Authors:  Carey D Balaban; Rolf G Jacob; Joseph M Furman
Journal:  Expert Rev Neurother       Date:  2011-03       Impact factor: 4.618

3.  Migraine Therapy: Current Approaches and New Horizons.

Authors:  Peter J Goadsby; Philip R Holland
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

4.  Donitriptan, but not sumatriptan, inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors.

Authors:  E Muñoz-Islas; S Gupta; L R Jiménez-Mena; J Lozano-Cuenca; A Sánchez-López; D Centurión; S Mehrotra; A MaassenVanDenBrink; C M Villalón
Journal:  Br J Pharmacol       Date:  2006-07-31       Impact factor: 8.739

Review 5.  Pathophysiology of Migraine: A Disorder of Sensory Processing.

Authors:  Peter J Goadsby; Philip R Holland; Margarida Martins-Oliveira; Jan Hoffmann; Christoph Schankin; Simon Akerman
Journal:  Physiol Rev       Date:  2017-04       Impact factor: 37.312

Review 6.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

7.  Profound reduction of somatic and visceral pain in mice by intrathecal administration of the anti-migraine drug, sumatriptan.

Authors:  Tetsuro Nikai; Allan I Basbaum; Andrew H Ahn
Journal:  Pain       Date:  2008-08-23       Impact factor: 6.961

8.  Episodic dural stimulation in awake rats: a model for recurrent headache.

Authors:  Michael L Oshinsky; Sumittra Gomonchareonsiri
Journal:  Headache       Date:  2007 Jul-Aug       Impact factor: 5.887

9.  Differential medication overuse risk of novel anti-migraine therapeutics.

Authors:  Chonlawan Saengjaroentham; Lauren C Strother; Isaac Dripps; Mohammad Rayhan Sultan Jabir; Amynah Pradhan; Peter J Goadsby; Philip R Holland
Journal:  Brain       Date:  2020-09-01       Impact factor: 13.501

Review 10.  A link between gastrointestinal disorders and migraine: Insights into the gut-brain connection.

Authors:  Sheena K Aurora; Stephen B Shrewsbury; Sutapa Ray; Nada Hindiyeh; Linda Nguyen
Journal:  Headache       Date:  2021-04-01       Impact factor: 5.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.